Morgan Stanley Increases Personalis (NASDAQ:PSNL) Price Target to $9.00

Personalis (NASDAQ:PSNL) had its price target upped by research analysts at Morgan Stanley from $5.00 to $9.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 12.36% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Guggenheim boosted their price objective on Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright boosted their price target on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Personalis in a research report on Wednesday, November 5th. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, Needham & Company LLC lifted their price target on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.29.

Personalis Stock Performance

PSNL opened at $8.01 on Tuesday. The firm has a 50 day moving average price of $7.54 and a 200 day moving average price of $6.17. The company has a market cap of $711.29 million, a PE ratio of -9.10 and a beta of 1.92. Personalis has a 1 year low of $2.83 and a 1 year high of $10.95.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The firm had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts predict that Personalis will post -1.4 earnings per share for the current year.

Insider Buying and Selling

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the transaction, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This trade represents a 16.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Personalis

Several large investors have recently modified their holdings of the stock. Aberdeen Group plc grew its stake in Personalis by 472.3% in the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock worth $5,984,000 after purchasing an additional 1,406,895 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Personalis by 165.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after buying an additional 851,422 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after acquiring an additional 802,268 shares in the last quarter. Blue Water Life Science Advisors LP increased its holdings in shares of Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after acquiring an additional 500,900 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Personalis by 1,172.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company’s stock valued at $2,164,000 after acquiring an additional 303,933 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.